Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin

Pain
Leslie J CroffordUma Sharma

Abstract

This was a multicenter, double-blind (DB), placebo-controlled, randomized discontinuation trial to evaluate the efficacy of pregabalin monotherapy for durability of effect on fibromyalgia (FM) pain. The trial included a 6-week open-label (OL) pregabalin-treatment period followed by 26-week DB treatment with placebo or pregabalin. Adults with FM and 40-mm score on 100-mm pain visual analog scale (VAS) were eligible. During OL weeks 1-3, patients received escalating dosages of pregabalin to determine their optimal dosages. During OL weeks 4-6, patients received their optimal fixed dosages (300, 450, 600mg/d). To be randomized, patients must have had 50% decrease in pain VAS and a self-rating of "much" or "very much" improved on Patient Global Impression of Change (PGIC) at the end of OL. Double-blind treatment was with placebo or the patient's optimal fixed dosage of pregabalin. Primary outcome was time to loss of therapeutic response (LTR), defined as <30% reduction in pain (from OL baseline) or worsening of FM. A total of 1051 patients entered OL; 287 were randomized to placebo, 279 to pregabalin. Time to LTR was longer for pregabalin versus placebo (P<.0001). Kaplan-Meier estimates of time-to-event showed half the placebo grou...Continue Reading

Associated Clinical Trials

References

Aug 9, 2001·Annals of Medicine·R D Hays, L S Morales
Mar 18, 2003·Journal of Clinical Pharmacology·Edward J RandinitisHoward N Bockbrader
Oct 7, 2003·Pain·Serge MarchandGary H Duncan
Apr 9, 2005·Arthritis and Rheumatism·Leslie J CroffordUNKNOWN Pregabalin 1008-105 Study Group
Apr 12, 2005·The Journal of Pain : Official Journal of the American Pain Society·Ralph W RichterLloyd E Knapp
May 11, 2006·Arthritis Research & Therapy·Roland Staud
Oct 4, 2006·Neuron·James N Campbell, Richard A Meyer
Nov 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mark J FieldDic Williams
Jan 16, 2007·Trends in Pharmacological Sciences·David J DooleyDouglas Feltner
Feb 20, 2007·Pain Practice : the Official Journal of World Institute of Pain·Edvin B Koshi, Christine Ann Short
Mar 25, 2008·Journal of Clinical Epidemiology·Jacques PouchotMatthew H Liang

❮ Previous
Next ❯

Citations

Jan 3, 2012·Rheumatology International·Boya NugrahaChristoph Gutenbrunner
Oct 10, 2007·Zeitschrift für Rheumatologie·P Harten
Sep 9, 2011·Zeitschrift für Rheumatologie·M Späth
Jul 5, 2012·Der Schmerz·C SommerUNKNOWN Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
Jun 10, 2010·Journal of General Internal Medicine·Michael C HsuDavid A Williams
Nov 1, 2008·Current Pain and Headache Reports·Philip J Mease, Kristin Seymour
Oct 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Danielle Perret, Z David Luo
Oct 15, 2008·Nature Clinical Practice. Neurology·Eric Serra
Jun 26, 2013·British Journal of Anaesthesia·R A MooreP J Wiffen
May 12, 2010·American Journal of Therapeutics·Eric S Hsu
Aug 18, 2012·International Journal of Rheumatic Diseases·Emma K GuymerGeoffrey O Littlejohn
Jul 7, 2010·BMC Musculoskeletal Disorders·Sebastian StraubeHenry J McQuay
Sep 22, 2010·BMC Musculoskeletal Disorders·Louise HumphreyClaire Gilbert
Jun 7, 2011·BMC Musculoskeletal Disorders·Sebastian StraubeHenry J McQuay
Jan 5, 2011·Journal of Pain Research·Chad S Boomershine
Apr 2, 2009·Neuropsychiatric Disease and Treatment·Grazyna Zareba
Apr 2, 2009·Neuropsychiatric Disease and Treatment·Kim Lawson
Sep 8, 2010·Clinical Drug Investigation·Gordon Irving
Jul 5, 2011·The Journal of Rheumatology·Philip J MeaseUNKNOWN OMERACT Fibromyalgia Working Group
Nov 3, 2009·Indian Journal of Psychiatry·Chittaranjan Andrade
Jun 11, 2014·Anesthesia and Analgesia·Michael J Buys, Carlo Alphonso
Jan 8, 2013·Current Rheumatology Reports·Yvonne C Lee
Sep 16, 2008·Journal of Women's Health·Christine N HuynhLaura A Morgan
Jul 3, 2010·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Yngve Mikkelsen
Jan 2, 2013·Journal of Clinical Psychopharmacology·Mario VitaliMaurizio Fava
Jul 17, 2009·Current Opinion in Anaesthesiology·Esther M Pogatzki-ZahnStephan A Schug
Jan 25, 2012·European Journal of Clinical Pharmacology·Gaetano ZaccaraPier Franco Gangemi
Feb 22, 2012·Journal of Medical Economics·Adam LloydGergana Zlateva
Dec 17, 2009·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Don L GoldenbergR Michael Gendreau
May 23, 2015·Expert Opinion on Pharmacotherapy·Elena P CalandreMahmoud Slim
Mar 1, 2009·Expert Review of Clinical Immunology·Emma Guymer, Geoffrey Littlejohn
Jun 26, 2012·Expert Opinion on Pharmacotherapy·Maree T Smith, Brendan J Moore
Sep 8, 2009·Expert Opinion on Investigational Drugs·Srinivas G Rao
Aug 4, 2011·Current Medical Research and Opinion·Peter SunPeter Watson
Feb 25, 2010·Current Medical Research and Opinion·Ernest ChoyGergana Zlateva

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.